Literature DB >> 10647718

Therapeutic options for capillary papillary hemangiomas.

J Garcia-Arumí1, L H Sararols, L Cavero, F Escalada, B F Corcóstegui.   

Abstract

PURPOSE: To describe the results and therapeutic complications of treatment of papillary capillary hemangiomas over the last 13 years.
DESIGN: Retrospective, noncomparative, interventional case series. PARTICIPANTS: Five cases of unilateral capillary papillary hemangiomas were reviewed. Three patients had von Hippel-Lindau disease, and two had no associated familial or systemic disease.
METHODS: Two patients were treated with argon green laser, one patient received argon green and diode photocoagulation, and two patients underwent argon green photocoagulation and diode transpupillary thermotherapy (TTT); two eyes also underwent vitreoretinal surgery. Follow-up ranged from 1 to 13 years. MAIN OUTCOME MEASURES: The presence of exudative retinal detachment associated with the activity of the hemangioma and the visual acuity were the two main parameters.
RESULTS: Prompt argon green laser treatment was the most effective therapy; -II was ineffective. Vitreoretinal surgery, transscleral drainage, and argon endolaser photocoagulation in one case resolved bullous retinal detachment secondary to tumor exudation. Pretreatment visual acuity (VA) levels ranged from 20/25 to counting fingers; posttreatment VA levels ranged from 20/25 to light perception.
CONCLUSIONS: If left untreated, papillary hemangiomas may evolve to exudative retinal detachment and marked VA decreases. Although we have not established an ideal therapy, we recommend appropriate treatment on diagnosis. Close follow-up and multiple treatments with argon laser are likely the best therapeutic course.

Entities:  

Mesh:

Year:  2000        PMID: 10647718     DOI: 10.1016/s0161-6420(99)00018-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  19 in total

1.  Total exudative detachment as a first presentation of von Hippel Lindau disease.

Authors:  A Ferguson; J Singh
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

2.  Juxtapapillary capillary hemangioma treated by intravitreal injection of bevacizumab combined with posterior subtenon injection of triamcinolone acetonide.

Authors:  Noriko Toyokawa; Hideya Kimura; Shinichiro Kuroda
Journal:  Jpn J Ophthalmol       Date:  2010-04-18       Impact factor: 2.447

Review 3.  [Capillary hemangioma of the retina in cases of von Hippel-Lindau syndrome. New therapeutic directions].

Authors:  N Bornfeld; K-M Kreusel
Journal:  Ophthalmologe       Date:  2007-02       Impact factor: 1.059

4.  Discrimination between normal and glaucomatous eyes with visual field and scanning laser polarimetry measurements.

Authors:  R Lauande-Pimentel; R A Carvalho; H C Oliveira; D C Gonçalves; L M Silva; V P Costa
Journal:  Br J Ophthalmol       Date:  2001-05       Impact factor: 4.638

5.  Ocular manifestations of von Hippel-Lindau disease: clinical and genetic investigations.

Authors:  Emily Ying Chew
Journal:  Trans Am Ophthalmol Soc       Date:  2005

Review 6.  Ophthalmological manifestations in VHL and NF 1: pathological and diagnostic implications.

Authors:  Klaus-Martin Kreusel
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

Review 7.  MANAGEMENT OF RETINAL HEMANGIOBLASTOMA IN VON HIPPEL-LINDAU DISEASE.

Authors:  Henry E Wiley; Valerie Krivosic; Alain Gaudric; Michael B Gorin; Carol Shields; Jerry Shields; Mary E Aronow; Emily Y Chew
Journal:  Retina       Date:  2019-12       Impact factor: 4.256

Review 8.  Ocular von Hippel-Lindau disease: clinical update and emerging treatments.

Authors:  Wai T Wong; Emily Y Chew
Journal:  Curr Opin Ophthalmol       Date:  2008-05       Impact factor: 3.761

9.  25-gauge vitrectomy combined with half-fluence photodynamic therapy for the treatment of juxtapapillary retinal capillary hemangioma: a case report.

Authors:  Cesare Mariotti; Alfonso Giovannini; Michele Reibaldi; Michele Nicolai; Andrea Saitta
Journal:  Case Rep Ophthalmol       Date:  2014-05-29

10.  Use of intravitreal bevacizumab in a patient with a Von Hippel-Lindau-associated retinal haemangioblastoma of the optic nerve head: a case report.

Authors:  Timothy A de Klerk; David H W Steel
Journal:  J Med Case Rep       Date:  2008-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.